cagliazine

Cagliazine is a novel small molecule dual inhibitor of sodium-glucose cotransporter 1 (SGLT1) and sodium-glucose cotransporter 2 (SGLT2), developed by researchers at the Sichuan Provincial People's Hospital. By targeting both SGLT2 in the kidneys and SGLT1 in the small intestine, cagliazine inhibits both the renal reabsorption of glucose and its intestinal absorption, potentially offering superior glycemic control and weight loss compared to selective SGLT2 inhibitors. Beyond its metabolic effects, cagliazine is being specifically investigated for its ability to treat oligomyopathy (muscle loss or sarcopenia) associated with diabetes and obesity. Preclinical studies have suggested that cagliazine may prevent muscle atrophy and improve muscle function, potentially by modulating the myostatin/Smad3 signaling pathway, making it a unique candidate for patients with metabolic disorders complicated by muscle wasting.

Other names

Caglizine卡格列嗪